id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-269469-7pmnxi9a	Bikdeli, Behnood	Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence	2020-10-08		.txt	text/plain	1060	72	42	[10] [11] [12] Such results were embraced by some clinicians and clinical institutions, leading to a change in their routine practice, including recommendations for escalated-dose prophylaxis in all, or some hospitalized patients with COVID-19. Multiple randomized trials have been registered and are at various stages of progress to identify the optimal antithrombotic therapy for outpatients, inpatients, and critically-ill patients with COVID-19. 18 In a pilot single-center study, the authors randomly The authors should be congratulated for completing the first randomized controlled trial of anticoagulant therapy in patients with COVID-19. Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study Intermediate versus Standard-dose Prophylactic anticoagulation and Statin Therapy versus Placebo in Critically-ill Patients with COVID-19: Rationale and Design of the INSPIRATION/ INSPIRATION-S Studies Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)	./cache/cord-269469-7pmnxi9a.txt	./txt/cord-269469-7pmnxi9a.txt